|
|
|
|
|
|
|
|
|
|
|
29.04.26 - 09:00
|
GSK Q1 Core Profit Rises; Affirms 2026 Guidance (AFX)
|
|
|
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - GSK (GSK, GSK.L, GS71.DE) reported first quarter pretax profit of 2.14 billion pounds compared to 2.11 billion pounds, prior year. Earnings per share was 42.6 ......
|
|
|
|
|
|
|
|
|
12.04.26 - 17:12
|
GSK reports promising early results in ovarian and womb cancer drug trial (The Guardian)
|
|
|
Mo-Rez reduced or eliminated tumours in over 60% of patients and is expected to be a blockbuster drugGSK has revealed positive results for a treatment for gynaecological cancers as its chief executive, Luke Miels, steps up drug development efforts at the group.The company said that in an early-stage trial Mocertatug Rezetecan, known as Mo-Rez, shrank or eliminated tumours in 62% of patients with ovarian cancer where chemotherapy had failed, and in 67% of those with endometrial cancer. Continue reading......
|
|
|
|
|
|
|
|
|
|
|
04.02.26 - 08:31
|
GSK Plc Profit Rises In Q4 (AFX)
|
|
|
LONDON (dpa-AFX) - GSK plc (GSK) revealed earnings for its fourth quarter that Increased, from last yearThe company's bottom line came in at GBP727 million, or GBP0.156 per share. This compares wi......
|
|
|
|
|
|
|
|
|
|
|
|
|
|